RxDoctor Payments Data

Karl Waite, MD

Ophthalmology · Daytona Beach, FLNPI 1598902579

Payments from drug & device makers

$11,156in general payments, 2019–2025

Across 215 payments — averaging $51.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • US Retina LLC$3K
  • Alimera Sciences, Inc.$2K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Astellas Pharma US Inc$1K
  • Genentech USA, Inc.$680
  • AbbVie$625
  • plus $2K from 8 others

What the payments were for

  • Speaking & faculty fees$1,39012%
  • Food & beverage$6,29856%
  • Ownership interest$3,46831%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,156 in reported general payments places this provider in the 80th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$5,503,118
Medicare patients
1,237
Services billed
53,694

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EyleaAflibercept179$455,100
VabysmoFaricimab-Svoa146$422,626
IzervayAvacincaptad Pegol Sodium/Pf49$144,900
Eylea HdAflibercept28$73,500
OzurdexDexamethasone18$38,444
Prednisolone Acetate189$5,382
Difluprednate47$4,369
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat149$2,312
Brimonidine Tartrate53$1,514
Loteprednol Etabonate17$1,254
Atropine Sulfate16$482
Latanoprost24$279
MoxifloxacinMoxifloxacin Hcl12$247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Regeneron Healthcare Solutions, Inc.Eylea, Eylea Hd$1,293$528,600207 claims
Genentech USA, Inc.Vabysmo$680$422,626146 claims
Astellas Pharma US IncIzervay$1,002$144,90049 claims
AbbVieOzurdex$625$38,44418 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$205$1,25417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Daytona Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →